GlassScriptPhysician profile
David Bryan Sigman
NPI 1356304497
$16,999.95
in general payments reported to CMS, 2019-2025
49 companies · $5,301 in 2025
The $5,301 reported for 2025 was more than what 91% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,449 · 2020: $306 · 2021: $1,482 · 2022: $2,303 · 2023: $3,632 · 2024: $1,527 · 2025: $5,301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,911 · Travel and Lodging: $2,549 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,910.91 |
| Travel and Lodging | $2,549.01 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avyxa Pharma, LLC | $3,357.60 | 2025 | |
| Sn Holdings, LLC | $2,160.00 | 2023 | |
| Neotract INC. | $1,363.15 | 2019 | |
| Boston Scientific Corporation | $974.36 | 2019-2025 | Spaceoar Vue System - 10ml, Advantage System, Ams 700 |
| Sumitomo Pharma America, INC. | $921.18 | 2023-2025 | Gemtesa, Orgovyx |
| Astellas Pharma US INC | $713.78 | 2019-2024 | Myrbetriq, Veozah, Xtandi |
| Teleflex LLC | $624.56 | 2021-2025 | Urolift, Barrigel |
| Janssen Biotech, INC. | $524.33 | 2019-2025 | Erleada, Akeega |
| Bayer Healthcare Pharmaceuticals INC. | $508.73 | 2019-2025 | |
| Endo Pharmaceuticals INC. | $442.40 | 2019-2024 | Xiaflex, Aveed |
| Ferring Pharmaceuticals INC. | $434.75 | 2019-2025 | Adstiladrin |
| Olympus America INC. | $422.43 | 2021-2023 | Itind System |
| Dendreon Pharmaceuticals LLC | $421.52 | 2019-2025 | Provenge |
| Urovant Sciences INC | $420.19 | 2021-2022 | |
| Tolmar Pharmaceuticals, INC. | $374.51 | 2019-2022 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $244.77 | 2019-2025 | |
| Amgen INC. | $240.78 | 2019-2022 | |
| Progenics Pharmaceuticals, INC. | $238.24 | 2021-2025 | Pylarify |
| Abbvie INC. | $218.67 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $208.89 | 2023-2025 | |
| Myriad Genetic Laboratories, INC. | $195.77 | 2021-2023 | |
| Myovant Sciences INC. | $192.59 | 2021-2022 | |
| Tolmar, INC. | $185.85 | 2023-2025 | Eligard, Jatenzo |
| Immunitybio, INC. | $179.20 | 2024-2025 | |
| Urogen Pharma, INC. | $169.31 | 2022-2025 | |
| Medtronic, INC. | $148.90 | 2022 | |
| Merck Sharp & Dohme LLC | $144.00 | 2021-2025 | Keytruda, Lynparza |
| Endo USA, INC. | $102.83 | 2024-2025 | Aveed, Xiaflex |
| Comsort, INC | $100.00 | 2019 | |
| Medtronic USA, INC. | $91.77 | 2019 | |
| Blue Earth Diagnostics | $80.18 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $69.91 | 2025 | Erleada |
| Antares Pharma, INC. | $60.84 | 2019-2022 | |
| Vertex Pharmaceuticals Incorporated | $57.68 | 2025 | |
| Accord Healthcare, INC. | $56.83 | 2023-2024 | |
| 180 Medical, INC. | $44.65 | 2022-2024 | Gentlecath Glide |
| Bioprotect Medical, INC. | $36.71 | 2024-2025 | Bioprotect Balloon Implant System |
| Avadel Specialty Pharmaceuticals, LLC | $34.12 | 2019 | |
| Genzyme Corporation | $30.82 | 2023 | |
| Rochester Medical Corporation | $30.76 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $26.60 | 2024 | Lynparza |
| Coloplast Corp | $25.67 | 2024 | |
| Palette Life Sciences, INC. | $23.97 | 2022 | |
| Allergan, INC. | $23.27 | 2019 | |
| Verity Pharmaceuticals INC. | $22.00 | 2025 | Trelstar |
| Caris Mpi, INC. | $18.27 | 2025 | Mi Cancer Seek |
| Telix Pharmaceuticals | $16.62 | 2023 | Illuccix |
| Tempus Ai, INC | $15.99 | 2024 | Xt Cdx |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$361,837.72 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Sigman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.